Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSY-2-12
- Development stage
- Preclinical
- Lead developer
- Keimyung University
01
Overview
PSY-2-12: sourced facts only. name: "In this study, we employed an HSP90-specific inhibitor, PSY-2-12 (PSY), to explore its potential therapeutic application as a senomorphic agent." [PMID:40953644]; target: "In this study, we employed an HSP90-specific inhibitor, PSY-2-12 (PSY), to explore its potential therapeutic application as a senomorphic agent." [PMID:40953644]; developer: "Department of Biochemistry, School of Medicine, Keimyung University, Daegu, South Korea." [PMID:40953644]; stage: "The anti-senescent effect of PSY was further confirmed in a mouse model of CP-induced acute kidney injury (AKI)." [PMID:40953644]
02
Targets
HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on PSY-2-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSY-2-12.